查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2153407

全球血管性水腫治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Angioedema Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 219 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球血管性水腫治療市場預計將從2025年的16.3億美元成長至2034年的39.2億美元，2026年至2034年的複合年成長率（CAGR）為10.23%。隨著醫療專業人員尋求有效治療血管性水腫的方法，該市場的重要性日益凸顯。血管性水腫的特徵是皮下和黏膜組織腫脹。血管性水腫可能與過敏反應、某些藥物或涉及發炎路徑異常的遺傳性疾病有關。人們對該疾病認知的提高、診斷能力的提升以及對遺傳性血管性水腫的深入了解，都在推動對合適治療方法的需求。早期發現和獲得適當的醫療照護仍然至關重要，因為發作會影響呼吸道，甚至危及生命。這些因素促使人們持續關注治療方案的取得和疾病管理。

市場成長的驅動力來自於標靶治療的進步、對疾病機制更深入的了解以及更多專業治療方案的可及性。治療方法因病因而異，包括用於治療過敏反應的急救藥物、針對遺傳性血管性水腫緩激肽路徑標靶治療以及針對合格患者的預防性治療。製藥公司正加大研發投入，旨在降低疾病發作頻率並改善疾病管理。專科護理的普及、病患教育計畫的開展以及診斷檢測技術的改進也促進了治療方案的廣泛應用。此外，更便捷的給藥方式的開發也有助於滿足患者的需求和治療管理要求。

該市場的未來前景將取決於標靶治療治療和預防性治療的進展，以及識別復發風險患者方法的改進。對新型生物學通路的研究可能為開發療效較佳、給藥更便捷的療法創造機會。提高對該疾病的診斷認知度也有助於減少遺傳性和藥物相關性血管性水腫的診斷延遲。然而，治療費用負擔、醫療資源分配不均以及嚴重發作時需要快速介入等問題仍需要重點考慮。持續的臨床研究、病患教育以及急救系統的改進有望進一步推動治療領域的發展。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球血管性水腫治療市場：依疾病類型分類

  • 市場分析、洞察與預測
  • 過敏性血管性水腫
  • 藥物引起的血管性水腫
  • 特發性血管性水腫
  • 遺傳性血管性水腫（HAE）

第5章 全球血管性水腫治療市場：依藥物類型分類

  • 市場分析、洞察與預測
  • C1酯酶抑制劑
  • 選擇性緩激肽B2受體拮抗劑
  • 激肽釋放酶抑制劑
  • 其他

第6章 全球血管性水腫治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 注射
  • 口服

第7章 全球血管性水腫治療市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院
  • 零售藥房
  • 網路藥房

第8章 全球血管性水腫治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Takeda
    • CSL
    • BioCryst Pharmaceuticals
    • Pharming Group
    • KalVista Pharmaceuticals
    • Ionis Pharmaceuticals
    • Pharvaris
    • Intellia Therapeutics
    • Astria Therapeutics
    • Adverum Biotechnologies
    • Arrowhead Pharmaceuticals
    • Sanofi
    • Attune Pharmaceuticals
    • ADARx Pharmaceuticals
    • Regeneron Pharmaceuticals
    • Otsuka Pharmaceutical
    • Grifols
    • Sobi
    • Octapharma
    • Kedrion Biopharma
簡介目錄
Product Code: VMR11219825

The global angioedema treatment market size is expected to reach USD 3.92 Billion in 2034 from USD 1.63 Billion in 2025, growing at a CAGR of 10.23% during 2026-2034.This market is gaining importance as healthcare professionals seek effective approaches to managing angioedema, a condition characterized by swelling beneath the skin or in mucosal tissues. Angioedema may be associated with allergic reactions, certain medications, or hereditary conditions involving abnormalities in inflammatory pathways. Growing awareness of the condition, improved diagnostic capabilities, and increasing recognition of hereditary angioedema are supporting demand for appropriate treatments. Because some episodes can involve the airway and become life-threatening, timely recognition and access to suitable medical care remain essential. These factors are encouraging continued attention to treatment availability and disease management.

Market growth is supported by advances in targeted therapies, improved understanding of disease mechanisms, and increasing availability of specialized treatment options. Treatments vary according to the underlying cause and may include emergency medications for allergic reactions, therapies targeting bradykinin pathways in hereditary angioedema, and preventive treatments for eligible patients. Pharmaceutical companies are investing in research aimed at reducing attack frequency and improving disease control. Greater access to specialist care, patient education programs, and improved diagnostic testing are also supporting treatment adoption. In addition, the development of more convenient administration methods is helping address patient preferences and treatment-management requirements.

The future prospects of this market will be influenced by advances in targeted treatment, preventive therapies, and improved approaches to identifying patients at risk of recurrent episodes. Research into novel biological pathways may create opportunities for therapies with improved effectiveness and dosing convenience. Better diagnostic awareness could also reduce delays in identifying hereditary and medication-related forms of angioedema. However, treatment affordability, differences in healthcare access, and the need for rapid intervention during severe episodes remain important considerations. Continued clinical research, patient education, and improvements in emergency preparedness are expected to support further development of the treatment landscape.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Condition Type

  • Allergic Angioedema
  • Drug-Induced Angioedema
  • Idiopathic Angioedema
  • Hereditary Angioedema (HAE)

By Drug Type

  • C1 Esterase Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others

By Route of Administration

  • Injection
  • Oral

By Distribution Channel

  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Takeda, CSL, BioCryst Pharmaceuticals, Pharming Group, KalVista Pharmaceuticals, Ionis Pharmaceuticals, Pharvaris, Intellia Therapeutics, Astria Therapeutics, Adverum Biotechnologies, Arrowhead Pharmaceuticals, Sanofi, Attune Pharmaceuticals, ADARx Pharmaceuticals, Regeneron Pharmaceuticals, Otsuka Pharmaceutical, Grifols, Sobi, Octapharma, Kedrion Biopharma

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANGIOEDEMA TREATMENT MARKET: BY CONDITION TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Condition Type
  • 4.2. Allergic Angioedema Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Drug-Induced Angioedema Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Idiopathic Angioedema Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Hereditary Angioedema (HAE) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANGIOEDEMA TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Type
  • 5.2. C1 Esterase Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Selective Bradykinin B2 Receptor Antagonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Kallikrein Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANGIOEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANGIOEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANGIOEDEMA TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Condition Type
    • 8.2.2 By Drug Type
    • 8.2.3 By Route Of Administration
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Condition Type
    • 8.3.2 By Drug Type
    • 8.3.3 By Route Of Administration
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Spain
    • 8.3.10 Russia
    • 8.3.11 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Condition Type
    • 8.4.2 By Drug Type
    • 8.4.3 By Route Of Administration
    • 8.4.4 By Distribution Channel
    • 8.4.5 China
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 India
    • 8.4.9 Australia
    • 8.4.10 South East Asia
    • 8.4.11 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Condition Type
    • 8.5.2 By Drug Type
    • 8.5.3 By Route Of Administration
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Condition Type
    • 8.6.2 By Drug Type
    • 8.6.3 By Route Of Administration
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ANGIOEDEMA TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Takeda
    • 10.2.2 CSL
    • 10.2.3 BioCryst Pharmaceuticals
    • 10.2.4 Pharming Group
    • 10.2.5 KalVista Pharmaceuticals
    • 10.2.6 Ionis Pharmaceuticals
    • 10.2.7 Pharvaris
    • 10.2.8 Intellia Therapeutics
    • 10.2.9 Astria Therapeutics
    • 10.2.10 Adverum Biotechnologies
    • 10.2.11 Arrowhead Pharmaceuticals
    • 10.2.12 Sanofi
    • 10.2.13 Attune Pharmaceuticals
    • 10.2.14 ADARx Pharmaceuticals
    • 10.2.15 Regeneron Pharmaceuticals
    • 10.2.16 Otsuka Pharmaceutical
    • 10.2.17 Grifols
    • 10.2.18 Sobi
    • 10.2.19 Octapharma
    • 10.2.20 Kedrion Biopharma